Portail HAL de l'Université Picardie Jules Verne
Not a member yet
32425 research outputs found
Sort by
EDUCAUSE 2025 French Delegation Report - EN: Visits to Vanderbilt University Arizona State University
No full textFor twelve years now, the French EDUCAUSE Delegation has offered the French Higher Educationcommunity an international perspective on digital issues, bringing together complementary profiles capable ofassessing key trends and major prospects. This approach has taken the form of continuous participation inthe EDUCAUSE Annual Conferences since 2013, which has been significantly enriched over the years. Froman initial philosophy of simple participation, the members of this Delegation have gradually become involvedat different levels of EDUCAUSE, both within the conferences and beyond (see infographic below).We now have twenty-four presentations that have been selected on a range of topical issues. Several of ourmembers are also involved each year as proposal reviewers for the EDUCAUSE Annual Conference, as wellas members of the respective Program Committees (in 2019, 2023, and 2026). Finally, some of us are part ofthe Expert Panels involved in the EDUCAUSE Horizon Report and the annual Top 10 Issues, are active invarious Community Groups (XR and Learning Spaces in particular), or are involved as writers of referencearticles and translators of tools.We should also mention the more than thirty on-site visits that have been conducted since 2013 before orafter the EDUCAUSE Annual Conferences, which, beyond the remarkable welcome we have always received,have provided us with invaluable insight into the field through high-quality exchanges
Splitting methods for the Gross-Pitaevskii equation on the full space and vortex nucleation
No full textWe prove the convergence in Zhidkov spaces of the first-order Lie-Trotter and the second-order Strang splitting schemes for the time integration of the Gross-Pitaesvkii equation with a time-dependent potential and non-zero boundary conditions at infinity. We also show the conservation of the generalized mass and the near-preservation of the Ginzburg-Landau energy balance law. Numerical accuracy tests performed on a one-dimensional dark soliton corroborate our theoretical findings. We finally investigate the nucleation of quantum vortices in two experimentally relevant settings
Applied improv to develop stress management in speech therapy students
No full textInternational audienc
P0785 One-Year Efficacy of Upadacitinib in Perianal Crohn’s Disease: A Multicenter Cohort Study.
No full textInternational audienceBackground Upadacitinib has demonstrated efficacy for induction and maintenance therapy in luminal Crohn’s disease (CD) (1). According to a post-hoc analysis of a phase 3 randomized controlled trial, upadacitinib also showed benefit in the treatment of fistulizing perianal CD (2). However, its real-world effectiveness in this specific phenotype has not yet been evaluated. Methods All consecutive patients with active perianal CD (primary and/or secondary lesions) treated with upadacitinib across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as the absence of draining pus including with pressure and healing of anal ulcers and/or fissures, without the addition of new dedicated treatment for perianal lesions (antibiotics and/or topics). Clinical response was defined as improvement of at least 50% of fistulas and/or ulcers by physician’s assessment. MRI-based response and remission were also assessed. Treatment failure was defined as upadacitinib discontinuation, initiation of a new advanced therapy, or need for additional perianal surgery. Patients lost to follow-up were considered as treatment failures. Results Fifty-nine patients were included: 43/59 (73%) with fistulizing perianal CD and 16/59 (27%) with isolated primary anal ulcerations. Median age was 38 years (interquartile range [29–47]); 29 (49%) were male and 11 (19%) were active smokers. All patients had previously been exposed to at least two biologics (median 4 [3–5]), and 40 (68%) had a history of perianal surgery, including 34/43 (79%) in the fistulizing subgroup. Among patients with fistulizing perianal CD, clinical remission was achieved in 5/43 (12%), 11/43 (26%), and 11/43 (26%) patients at 3, 6, and 12 months, respectively, while clinical response was observed in 27/43 (63%), 21/43 (49%), and 13/43 (30%) patients (Figure 1). At 12 months, MRI response was documented in 9/14 (64%) and MRI remission in 1/14 (7%) patients with fistulizing perianal CD. Among those with isolated anal ulcerations, complete ulcer healing was observed in 4/16 (25%) at 12 months (Figure 1). No clinical or demographic factors were associated with clinical remission at 12 months in univariate analysis. Sixteen adverse events (AEs) were reported in 14 patients (27%), including three (5%) serious AEs corresponding to CD exacerbations. At 12 months, 10 patients (17%) underwent perianal drainage surgery, and 16 (27%) discontinued upadacitinib, all due to lack of efficacy. Conclusion In this real-world multicentre cohort of patients with refractory perianal CD, treatment with upadacitinib achieved clinical remission in approximately one-quarter of patients at one year. References: (1) Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966-1980. (2) Colombel JF, Lacerda AP, Irving PM, et al. Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials. Clin Gastroenterol Hepatol. 2024;0(0). Conflict of interest: Dr. Richard, Nicolas: Lecture/consultant fees from AbbVie, Amgen, Celltrion, Ferring, Janssen, Lilly, Sandoz and Takeda. Seksik, Philippe: I received personal fees from Takeda, Janssen, Merck MSD, Biocodex, Ferring, Fresenius Kabi, Astellas, Amgen, Pfizer, Pilege and Abbvie Altwegg, Romain: Advisory boards from Abbvie, Takeda, Johnson and Johnson, Lilly, Alphasigma, Celltrion, Pfizer, Amgen, Biogen, Sandoz, Ferring Nachury, Maria: Abbvie, Alfa Sigma, Biosynex, Celltrion, Galapagos, Janssen, Lilly, MSD, Pfizer, Takeda Laharie, David: Personal Fees: Board, consulting and lecture fees from Abbvie, Alfasigma, Amgen, Biocon, Celltrion, Ferring, Fresenius-Kabi, Johnson & Johnson, Lilly, MSD, Pfizer, Sandoz and Takeda Nancey, Stéphane: board membership and lecturing fees from Abbvie, Takeda, Celltrion Healthcare, Pfizer, Galapagos, Johnson & Jonshon, Lilly, Fresenius, Amgen, Medac, MSD. Coffin, Benoît: No conflict of interest Pelletier, Anne-Laure: •ALP has received lecture/consultant fees from Janssen, Pfizer, and Novartis. Uzzan, Mathieu: Grant: ECCO-IOIBD, Fondation pour la Recherche Medicale (FRM), SNFGE Personal Fees: Abbvie, Takeda, Celltrion, Janssen, Amgen, Alfasigma, Pfizer Amiot, Aurelien: Personal Fees: Abbvie, Fresenius-Kabi, Adacyte, Tillotts pharma, Janssen, Pfizer, Biogen, AMgen, Sandoz, Takeda, Galapagos, Eli Lilly Amil, Morgane: No conflict of interest Vuitton, Lucine: •LV has received fees for lectures and/or consulting fees from Abbvie, Amgen, Johnson & Johnson, Celltrion, Takeda, Pfizer, Lilly, Ferring, MSD, Dr Falk Pharma, Nordic Pharma, Alpha sigma. Fumery, Mathurin: •M.F. has received lecture/consultant fees from AbbVie, Ferring, Tillotts, MSD, Biogen, Amgen, Fresenius, Hospira, Sandoz, Pfizer, Celgene, Gilead, Boehringer, Galapagos, Janssen, and Takeda. N.R. has received lecture/consultant fees from AbbVie, Janssen and Takeda. Bozon, Anne: No conflict of interes
Invasive plants optimize leaf nitrogen allocation in photosynthesis
No full textInternational audienceInvasive plants often outcompete co‐occurring native species by expressing acquisitive functional traits that promote high photosynthetic capacity. However, it remains unclear whether these traits are newly evolved in the introduced (‘away’) range or if invaders arrived preadapted with superior traits from their native (‘home’) range. We measured photosynthetic performance of 27 invasive species in their home and away ranges, along with 17 co‐occurring native species across 414 populations in temperate forest and field habitats. To understand mechanisms of photosynthetic shifts, we quantified leaf nitrogen (N) allocation among photosynthetic, structural, and defensive functions. Invasive species had greater photosynthetic capacity and photosynthetic N allocation than natives in both habitats, despite similar total leaf N. In fields, away‐range invaders increased Rubisco investment compared to home populations, enhancing carboxylation rates. In forests, invaders had greater Chl allocation and quantum yield compared to native species – advantages already present in home‐range populations. Increased photosynthetic N allocation was not linked to reduced structural or defensive N pools, challenging the hypothesis that invader growth advantages come at the expense of defense. Our findings suggest that enhanced N investment in photosynthesis is a common competitive advantage of invasive species, involving both away‐range evolution and preadaptation
Écritures de l'ordinaire : pour une approche pragmatique de la littérature: A propos de Maryline Heck, Écriture et expérience de la vie ordinaire. Perec, Ernaux, Vasset, Quintane, Bruxelles : La lettre volée, coll. « Essais », 352 p., 2023, EAN 9782873176174.
No full textInternational audienceDans la lignée des travaux récents sur les esthétiques du quotidien en littérature, cet ouvrage de Maryline Heck s’intéresse aux rapports qu’entretiennent les écritures contemporaines de l’ordinaire avec la notion d’expérience. L’auteure propose pour ce faire quatre études consacrées aux œuvres de George Perec, Annie Ernaux, Philippe Vasset et Nathalie Quintane. Inspirée par ces auteurs, et à partir d’outils critiques venus des études littéraires, de l’art contemporain, des philosophies de l’ordinaire ou encore des théories du care ou de l’attention, M. Heck propose une « approche pragmatique » qui questionne à nouveaux frais la possibilité d’un agir concret de la littérature contemporaine
Prise en charge clinique et thérapeutique des hépatopathies stéatosiques associées à une dysfonction métabolique (MASLD)
No full textInternational audienceMetabolic dysfunction–associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease worldwide. It arises from complex interactions between genetic susceptibility, excessive caloric intake, sedentary lifestyle, and insulin resistance, predominantly affecting individuals with obesity or type 2 diabetes. Approximately 20% of patients with MASLD progress to metabolic dysfunction–associated steatohepatitis (MASH), which may further evolve to fibrosis, cirrhosis, and hepatocellular carcinoma. Management prima¬rily relies on lifestyle interventions aimed at weight loss, including adherence to a Mediterranean diet, increased physical activity, and reduction of sedentary behavior, with bariatric surgery indicated in severe obesity. Recent therapeu¬tic advances include resmetirom, a thyroid hormone receptor β agonist and the first approved pharmacological treatment for MASH, as well as GLP-1 receptor agonists, co-agonists, pan-PPAR agonists, and FGF21 analogues, all demonstrating promising effects on MASH resolution and fibrosis improve¬ment. Non-invasive biological scores may play a central role in evaluating disease severity and therapeutic response, positioning clinical laboratories at the core of patient management.Les hépatopathies stéatosiques associées à une dysfonction métabolique (MASLD pour metabolic dysfunction-associated steatotic liver disease) constituent aujourd’hui la principale cause de maladie hépatique. Elles résultent d’interactions entre facteurs génétiques, excès alimentaire, sédentarité et insulino-résistance, et touchent surtout les personnes obèses ou diabétiques. Environ 20 % des pala sédentarité. La chirurgie bariatrique est indiquée pour les obésités sévères. De nouvelles options thérapeutiques émergent, notamment le resmétirom agoniste du récepteur thyroïdien β, premier traitement approuvé pour la MASH, les agonistes du GLP-1 (sémaglutide), les co-agonistes (tirzépatide), les agonistes pan-PPAR (lanifibranor) et les analogues du FGF21 (éfruxifermine, pégozafermine). Toutes ces molécules ont montré des résultats encourageants sur la résolution de la MASH et l’amélioration de la fibrose. L’évaluation de ces traitements pourra faire appel aux scores biologiques non invasifs, plaçant le laboratoire de biologie médicale au coeur du suivi thérapeutique